Journal Article

FZJ-2020-01446

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png mGluR5 receptor availability is associated with lower levels of negative symptoms and better cognition in male patients with chronic schizophrenia

Régio Brambilla, C. (Corresponding author)FZJ* ; Veselinović, T. ; Rajkumar, R.FZJ* ; Mauler, J.FZJ* ; Orth, L. ; Ruch, A. ; Ramkiran, S.FZJ* ; Heekeren, K. ; Kawohl, W. ; Wyss, C. ; Kops, E. R.FZJ* ; Scheins, J.FZJ* ; Tellmann, L.FZJ* ; Boers, F.FZJ* ; Neumaier, B.FZJ* ; Ermert, J.FZJ* ; Herzog, H.FZJ* ; Langen, K.FZJ* ; Jon Shah, N. ; Lerche, C.FZJ* ; Neuner, I.FZJ*

2020
Wiley-Liss New York, NY

This record in other databases:      

Please use a persistent id in citations: http://hdl.handle.net/2128/25107  doi:10.1002/hbm.24976

Abstract: Consistent findings postulate disturbed glutamatergic function (more specifically a hypofunction of the ionotropic NMDA receptors) as an important pathophysiologic mechanism in schizophrenia. However, the role of the metabotropic glutamatergic receptors type 5 (mGluR5) in this disease remains unclear. In this study, we investigated their significance (using [11C]ABP688) for psychopathology and cognition in male patients with chronic schizophrenia and healthy controls. In the patient group, lower mGluR5 binding potential (BPND) values in the left temporal cortex and caudate were associated with higher general symptom levels (negative and depressive symptoms), lower levels of global functioning and worse cognitive performance. At the same time, in both groups, mGluR5 BPND were significantly lower in smokers (F [27,1] = 15.500; p = .001), but without significant differences between the groups. Our findings provide support for the concept that the impaired function of mGluR5 underlies the symptoms of schizophrenia. They further supply a new perspective on the complex relationship between tobacco addiction and schizophrenia by identifying glutamatergic neurotransmission—in particularly mGluR5—as a possible connection to a shared vulnerability.

---

Contributing Institute(s):

1. Jara-Institut Quantum Information (INM-11)
2. Physik der Medizinischen Bildgebung (INM-4)
3. JARA-BRAIN (JARA-BRAIN)
4. Nuklearchemie (INM-5)

Research Program(s):

1. 573 - Neuroimaging (POF3-573) (POF3-573)

Appears in the scientific report 2020

---

Database coverage:
; ; ; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; IF < 5 ; JCR ; NCBI Molecular Biology Database ; Nationallizenz ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---